Not sure what you hope to achieve by stating it in AUD other than make the number seem larger.
The trial itself isn't fluff but it isn't really anything other than an indication of how early in the process RSH is- as i said its a trial to test its effectiveness. Whether it actually does anything worthwhile. It seems we are so far behind where we should be in commercialisation to the point where the 'most credible respiratory groups in the world' aren't even sure if the product is worthwhile.
All the other comments in reply to mine are fair, interim results etc, albeit some tend to get overly offended by different opinions.
As always with this stock, time will tell. So far the naysayers have been correct unfortunately. Nothing that's been spruiked here has ever really come to fruition, people should just cop that they've been incorrect and try and work with facts.
Apply as much rhetoric to the discussion as you like but every year it's 'this is the year' only to be a major commercial and subsequent share market disappointment story.
Having the trial isn't a distraction for the company in terms of US developments, obviously. What I meant is don't let the announcement cloud the fact that we've been told to expect big things from US imminently. Instead of that news we get news on a trial in a totally different location on whether wheezo even works.
I hope we don't hear next 'US didn't work out, but with the trial in the UK, we are switching focus to there and expect big things.... in 2024'
RSH Price at posting:
5.2¢ Sentiment: Hold Disclosure: Held
